Interpace Diag Group (IDXG)

$1.07 +0.12 (12.37%)
Market Cap 4.20M
Revenue (ttm) 46.93M
Net Income (ttm) 6.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 14.28%
Debt to Equity Ratio 0.00
Volume 9,600
Avg Vol 9,056
Day's Range N/A - N/A
Shares Out 4.42M
Stochastic %K 100%
Beta 1.06
Analysts Strong Buy
Price Target $11.00

Company Profile

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 855 776 6419
Address:
Waterview Plaza, Suite 310 2001 Route 46, Parsippany, United States
Zapp
Zapp Dec. 4 at 1:22 AM
$IDXG great news re: early payoff of 2021 BroadOak debt. Time for a 🚀
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG 2/2 With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG PARSIPPANY, NJ , Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021 , with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest expenses, providing increased operational flexibility to support future growth. “The early repayment of the BroadOak facility is a significant milestone for Interpace and a testament to our robust financial performance and disciplined capital management,” said Chris McCarthy , Chief Financial Officer. “Over the past several years, BroadOak has been a valuable partner, supporting our strategic turnaround and transition to profitability.
0 · Reply
Waters59
Waters59 Dec. 2 at 2:53 PM
$IDXG Let's Go!! 📈 Pick up those cheap shares!
0 · Reply
Waters59
Waters59 Nov. 25 at 1:25 PM
$IDXG Time for a reversal! 🚀
0 · Reply
Esau815
Esau815 Nov. 13 at 1:36 PM
$IDXG Agreed. More than respectable quarter. Believe that the plan is to be DONE with the debt by year end. Almost miraculoulous that they were able to stall PancraGen's demise by 18 months to get that debt paid off AND to heave Preferred's convert. Let's see if they can sell this as a debt free company with $35MM in revenues and positive EBITDA. Elimination of interest and debt outstanding will immensely help with cash flow going into 2026.
0 · Reply
Waters59
Waters59 Nov. 12 at 9:39 PM
$IDXG The results were actuall good considering this is the first full quarter of the Company being a Thyroid-only diagnostics testing company. https://www.interpace.com/news-media/press-releases/detail/245/interpace-biosciences-announces-third-quarter-2025
0 · Reply
apppro
apppro Nov. 12 at 9:18 PM
$IDXG OK they just reported. OK not out of business, but not good either.
0 · Reply
Waters59
Waters59 Nov. 12 at 2:46 PM
$IDXG Let's Go! 🚀
0 · Reply
apppro
apppro Nov. 10 at 4:44 PM
$IDXG when do these idiots report?? I have on calender today but who the F knows anymore
0 · Reply
Latest News on IDXG
No data available.
Zapp
Zapp Dec. 4 at 1:22 AM
$IDXG great news re: early payoff of 2021 BroadOak debt. Time for a 🚀
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG 2/2 With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving commercial growth as we continue to deliver record testing volumes and revenue for our thyroid tests.”
0 · Reply
davoid57
davoid57 Dec. 3 at 8:48 PM
$IDXG PARSIPPANY, NJ , Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021 , with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest expenses, providing increased operational flexibility to support future growth. “The early repayment of the BroadOak facility is a significant milestone for Interpace and a testament to our robust financial performance and disciplined capital management,” said Chris McCarthy , Chief Financial Officer. “Over the past several years, BroadOak has been a valuable partner, supporting our strategic turnaround and transition to profitability.
0 · Reply
Waters59
Waters59 Dec. 2 at 2:53 PM
$IDXG Let's Go!! 📈 Pick up those cheap shares!
0 · Reply
Waters59
Waters59 Nov. 25 at 1:25 PM
$IDXG Time for a reversal! 🚀
0 · Reply
Esau815
Esau815 Nov. 13 at 1:36 PM
$IDXG Agreed. More than respectable quarter. Believe that the plan is to be DONE with the debt by year end. Almost miraculoulous that they were able to stall PancraGen's demise by 18 months to get that debt paid off AND to heave Preferred's convert. Let's see if they can sell this as a debt free company with $35MM in revenues and positive EBITDA. Elimination of interest and debt outstanding will immensely help with cash flow going into 2026.
0 · Reply
Waters59
Waters59 Nov. 12 at 9:39 PM
$IDXG The results were actuall good considering this is the first full quarter of the Company being a Thyroid-only diagnostics testing company. https://www.interpace.com/news-media/press-releases/detail/245/interpace-biosciences-announces-third-quarter-2025
0 · Reply
apppro
apppro Nov. 12 at 9:18 PM
$IDXG OK they just reported. OK not out of business, but not good either.
0 · Reply
Waters59
Waters59 Nov. 12 at 2:46 PM
$IDXG Let's Go! 🚀
0 · Reply
apppro
apppro Nov. 10 at 4:44 PM
$IDXG when do these idiots report?? I have on calender today but who the F knows anymore
0 · Reply
Waters59
Waters59 Nov. 10 at 4:38 PM
$IDXG
0 · Reply
Waters59
Waters59 Nov. 3 at 8:00 PM
$IDXG Don't let this go back down. Chug-a-lug! 🚀
0 · Reply
Waters59
Waters59 Oct. 31 at 3:01 PM
$IDXG Eat those shares! Gobble gobble. Let's Go! 🚀
0 · Reply
crane_train21
crane_train21 Oct. 30 at 11:00 PM
$IDXG I dumped shares and it bumped immediately lmao
1 · Reply
Waters59
Waters59 Oct. 30 at 11:59 AM
$IDXG Let's go baby! 🚀 🚀
0 · Reply
Waters59
Waters59 Oct. 29 at 12:55 PM
$IDXG Yes! Gobble up those shares! 🚀 Let's go!
0 · Reply
Waters59
Waters59 Oct. 28 at 2:38 PM
$IDXG Let's go! Gobble up thos shares! 🚀 lol
0 · Reply
Waters59
Waters59 Oct. 27 at 12:12 PM
$IDXG Gobble up those shares! Let's break $1! 🚀
0 · Reply
Waters59
Waters59 Oct. 13 at 11:54 AM
$IDXG Break that wall! Let's Go!
0 · Reply
Waters59
Waters59 Oct. 1 at 4:15 PM
$IDXG climb that ladder
0 · Reply
Waters59
Waters59 Sep. 26 at 1:59 PM
$IDXG About time this does something....
0 · Reply
Waters59
Waters59 Sep. 24 at 2:34 PM
$IDXG Sell the company already!
0 · Reply